The European Medicines Agency (EMA) is moving ahead to relocate to one of the remaining 27 European Union member states. The Europen Council is expected to make a decision on the new location in October of this year. The agency has begun impact assessment studies to help prepare for the move and retain as many staff as possible, according to the EMA.
The EMA has started on the re-distribution of the workload relating to the evaluation and monitoring of medicines to ensure the quality of EMAs scientific assessments and compliance with legal timelines. There is a group for human medicines and one for veterinary medicines to allocate the workload.
The agency is also working on the provision of guidance and information to pharma companies.
Additionally, the EMA announced that the EU clinical trial portal and database’s go-live date has been postponed, due to technical issues with the IT systems. EMA said it is working closely with its IT service provider to ensure that corrective measures are implemented and will closely monitor progress.
The agency will provide an update at the next meeting of the Management Board in October 2017. Due to these delays, the EU Clinical Trial Regulation will now come into application in 2019 instead of October 2018, as previously scheduled.
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.